Phase II trial of Sorafenib and Capecitabine in Advanced Renal Cell Carcinoma (RCC)

Phase II trial of Sorafenib and Capecitabine in Advanced Renal Cell Carcinoma (RCC) - Sorafenib and Capecitabine in Renal Cell Carcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON32358

Enrollment

Registered

2008-01-22

Start date

2007-10-24

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney cancer renal cell carcinoma

Interventions

Two drugs: Sorafenib and Capecitabine

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Advanced renal cell carcinoma (metastatic RCC)

Exclusion criteria

Exclusion criteria: Other types of malignancies History of cardiac disease Serious clinical infections Symptomatic brain metastases

Design outcomes

Primary

Measure	Time frame
Progression free survival at 12 months	—

Secondary

Measure	Time frame
Overall remission Overall survival Safety	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)